Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer clinical trial (NCT02907918). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this combination treatment compare to other options available to me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer clinical trial (NCT02907918). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of palbociclib, letrozole, and trastuzumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer clinical trial (NCT02907918). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatments and tests if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer clinical trial (NCT02907918). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer clinical trial (NCT02907918). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer clinical trial (NCT02907918). Contact the study team or your healthcare provider for specific answers.

What this study is about